Powered By
Continue with Facebook
Continue with Email
When muscle-invasive bladder cancer (MIBC) spreads to the lymph nodes, it often means treatment will be more aggressive. That’s because cancer found in the lymph nodes indicates that it has spread beyond the bladder and may have a greater risk of spreading to other parts of the body.
If you or someone you know has been diagnosed with MIBC, one of the first things your doctor will want to know is whether the cancer has reached the lymph nodes. This information helps determine the cancer stage (how far the cancer has spread), estimate your prognosis (outlook), and guide your MIBC treatment plan.
Lymph nodes are small, bean-shaped structures that are part of the immune system Typically, humans have about 400 to 800 lymph nodes scattered throughout the body. Their job is to trap infections, damaged cells, and foreign substances.
For example, when people have a sore throat or a cold, they may notice that the “glands” in their neck are swollen. These are actually lymph nodes responding to infection.
In muscle-invasive bladder cancer, cancer cells can sometimes break away from the original tumor and travel through the lymphatic system, a network of vessels, tissues, and organs that carries lymph fluid throughout the body. The cancer cells may get trapped in nearby lymph nodes and start growing there. When this happens, it means the cancer has moved beyond the bladder.
Staging is how your cancer care team determines the extent of cancer spread. It pulls information from your physical exams, biopsies, imaging tests, and surgery to build a complete picture of how cancer is affecting your body.
You’ll likely hear your doctors use the term “regional lymph nodes.” These are the lymph nodes closest to the bladder.
Think of your lymphatic system like a railway network running through your body. In muscle-invasive bladder cancer, the cancer has already invaded the bladder muscle. So a common next stop on that railway is the surrounding regional lymph nodes.
When that happens, the cancer is referred to as “node-positive.”
Doctors stage node-positive MIBC using the TNM system. Each letter refers to a different aspect of how far the cancer has spread:
Muscle-invasive bladder cancer is at least stage 2 when it has grown into the bladder muscle but has not spread to lymph nodes or distant parts of the body. (Cancer stages are sometimes written using Roman numerals, such as stage III instead of stage 3.)
The N category in the TNM staging system describes whether cancer has spread to regional lymph nodes — lymph nodes near the bladder — and how many are involved:
For bladder cancer that has not spread to distant parts of the body, N1 disease is generally classified as stage 3A, while N2 or N3 disease is classified as stage 3B.
Bladder cancer is classified as stage 4A if the tumor has grown into the pelvic or abdominal wall (T4b) or if cancer has spread to distant lymph nodes beyond the common iliac arteries (M1a).
Cancer that has spread to distant organs, such as the lungs, liver, or bones, is classified as stage 4B (M1b).
The higher the N category, the more advanced the stage and, generally, the more complex the treatment plan.
Doctors can determine whether MIBC has spread to the lymph nodes both before and after surgery.
Before doctors confirm someone has MIBC, the person may have a cystoscopy (a procedure that uses a thin camera to look inside the bladder) and a transurethral resection of bladder tumor (TURBT, a procedure that removes tissue from the bladder for testing). These procedures help doctors determine whether the cancer has grown into the bladder muscle.
A person may also have imaging scans, such as a CT scan and an MRI. These scans check the urinary tract and look for signs that the cancer has spread to nearby lymph nodes.
When imaging suggests that cancer has spread to the lymph nodes, this is called clinically node-positive disease. This helps your doctors factor nodal involvement into your treatment plan from the very beginning.
During a radical cystectomy (surgery to remove the bladder), surgeons usually remove nearby lymph nodes in a procedure called a pelvic lymph node dissection. The lymph nodes are then examined under a microscope.
If cancer cells are found, the cancer is considered pathologically node-positive. This information may help determine whether additional treatment, such as chemotherapy or immunotherapy, is recommended after surgery.
Imaging doesn’t detect all cases of lymph node involvement. Researchers have found that up to 25 percent of people whose lymph nodes appear negative on imaging are later found to have positive lymph nodes once surgical pathology results return.
This can happen because cancer cells can be too small to detect on a scan, a phenomenon known as microscopic nodal disease. As such, surgically removing and testing the lymph nodes remains an important component of MIBC treatment.
Prognosis is an estimate of how a condition may affect a person over time, including the chances of responding to treatment, cancer returning, and survival.
Lymph node involvement is generally associated with a less favorable prognosis than MIBC that hasn’t spread beyond the bladder.
According to the National Cancer Institute, the five-year relative survival rate for regional bladder cancer — which includes cancer that has spread to nearby tissues or regional lymph nodes — is about 39 percent. This means that people with regional bladder cancer are about 39 percent as likely as people in the general population to be alive five years after diagnosis.
The figure is based on outcomes in large groups of people and cannot predict what will happen to any one person.
A MyBladderCancerTeam member said, “I was diagnosed with MIBC, which spread to four local lymph nodes. I have my bladder and currently no evidence of disease, and feel great.”
Every individual is different, and responses to node-positive cancer treatment may vary.
Other factors that influence prognosis include:
It’s also possible for muscle-invasive bladder cancer to recur (return) after therapy. Among people with node-positive MIBC who undergo cystectomy, the recurrence rate is around 70 percent.
Staying on top of your follow-up appointments after ringing the cancer-free bell is important for proper surveillance and improved quality of life.
Your doctors can also help you understand what shapes your prognosis.
The goal of treating MIBC with lymph node metastasis is to address both the bladder tumor and any cancer that’s spread.
Available treatment options include chemotherapy, immunotherapy, surgery, and radiation.
For most people with MIBC who are fit enough — particularly those with adequate kidney function — the standard first step is cisplatin-based chemotherapy given before surgery (neoadjuvant chemotherapy), increasingly combined with immunotherapy. Around half of people with MIBC aren't candidates for cisplatin, so their treatment is individualized.
Neoadjuvant chemotherapy in node-positive disease can shrink the tumor and kill cancer cells in the lymph nodes before surgery. It can also target any microscopic cancer cells that may have spread elsewhere in the body but aren’t yet visible on scans.
The gold-standard surgical treatment for MIBC is radical cystectomy. In node-positive disease, this surgery typically includes a pelvic lymph node dissection (PLND), where the surgeon removes regional lymph nodes along with the bladder. This remains the standard approach for eligible people with MIBC because it helps accurately stage the cancer and remove cancer that may have spread to nearby lymph nodes.
Removing additional lymph nodes beyond the standard pelvic area hasn’t consistently been shown to improve outcomes and isn’t routinely recommended. For some carefully selected people, bladder-preserving treatment may also be an option, depending on the stage of the cancer, overall health, and personal treatment goals.
Depending on your specific case, adjuvant treatment (after surgery) may include additional chemotherapy, radiation, or immunotherapy. The decision is highly individualised, and your doctors will consider your test results, overall health, and your body’s response to treatment so far to decide the best next step for you.
Emerging therapies in MIBC care are rapidly evolving. Researchers continue to study new treatment breakthroughs, smarter imaging tools, and ways to preserve the bladder.
Here are key advances to help you make informed decisions with your doctors.
Immunotherapy has become an important part of treatment for some people with muscle-invasive bladder cancer. Unlike chemotherapy, which directly attacks cancer cells, immunotherapy helps your immune system recognize and destroy cancer cells.
For people who are eligible, a combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) is now approved by the U.S. Food and Drug Administration (FDA). In this combination, pembrolizumab is the immunotherapy drug, while enfortumab vedotin is an antibody-drug conjugate — a medicine that delivers cancer-killing treatment directly to tumor cells.
Your care team will determine whether this combination, chemotherapy, or another treatment approach is most appropriate based on your overall health, cancer stage, and treatment goals.
Researchers also continue to study additional immunotherapy combinations and other new treatment strategies to further improve outcomes for people with MIBC.
A newer type of scan called a positron emission tomography (PET)-CT may outperform a standard CT scan at detecting muscle-invasive bladder cancer that’s spread to lymph nodes.
In one retrospective study, people with MIBC staged with PET-CT were later found to develop distant metastases far less often than those staged with CT alone (9.5 percent versus 43.1 percent).
However, PET-CT isn’t routinely used for everyone during initial staging. Doctors may recommend it when standard scans are unclear or when they need to look more closely for signs that the cancer has spread.
Bladder-preserving trimodality therapy — maximal tumor resection (removing as much of the tumor as possible during TURBT), followed by chemotherapy and radiation — is an established alternative to bladder removal. For some people, it can offer cancer outcomes comparable to radical cystectomy while sparing the bladder.
Current evidence supports offering bladder-preserving trimodality therapy to all suitable candidates through shared decision-making, not only to those who cannot tolerate surgery.
If standard treatments have not worked or your cancer has returned, ask your doctor about clinical trials. These studies offer access to interventions that are not yet widely available and may open doors to new options tailored to your situation.
On MyBladderCancerTeam, people share their experiences with bladder cancer, get advice, and find support from others who understand.
Have you been told your cancer has spread to your lymph nodes, and how did that change your treatment plan? Let others know in the comments below.
Get updates directly to your inbox.
Continue with Facebook
Continue with Email
Continue with Facebook
Continue with Email
Become a member to get even more
Join
Your Privacy Choices
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.